SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-148162
Filing Date
2023-05-18
Accepted
2023-05-18 16:20:02
Documents
14
Period of Report
2023-05-18
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d504530d8k.htm   iXBRL 8-K 24409
2 EX-99.1 d504530dex991.htm EX-99.1 18086
6 GRAPHIC g504530dsp5.jpg GRAPHIC 6269
  Complete submission text file 0001193125-23-148162.txt   183084

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stsa-20230518.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20230518_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20230518_pre.xml EX-101.PRE 11712
8 EXTRACTED XBRL INSTANCE DOCUMENT d504530d8k_htm.xml XML 3448
Mailing Address 4819 EMPEROR BOULEVARD SUITE 340 DURHAM NC 27703
Business Address 4819 EMPEROR BOULEVARD SUITE 340 DURHAM NC 27703 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39041 | Film No.: 23936364
SIC: 2834 Pharmaceutical Preparations